Edil San Felice S.p.A. (BIT:ESF)

Ligand Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2019
Operating Revenue	39.23	41.66	31.52	27.53	17.9
Other Revenue	1.1	1.15	0.77	0.49	-
Revenue	40.33	42.81	32.3	28.02	18.05
Revenue Growth (YoY)	-5.80%	32.57%	15.26%	55.20%	27.82%
Cost of Revenue	12.66	17.58	14.88	13.49	4.22
Gross Profit	27.67	25.24	17.42	14.53	13.83
Selling, General & Admin	17	13.74	10.37	10.06	4.18
Other Operating Expenses	1.24	-0.14	0.2	0.04	7.34
Operating Expenses	19.56	14.65	11.04	10.4	11.79
Operating Income	8.11	10.59	6.38	4.12	2.04
Interest Expense	-0.33	-0.33	-0.13	-0.02	-
Earnings From Equity Investments	0.03	0.02	-	-	-
Other Non Operating Income (Expenses)	0.21	0.05	0	0.04	-0.01
EBT Excluding Unusual Items	8.03	10.33	6.25	4.15	2.03
Gain (Loss) on Sale of Investments	-	-0	-0.04	-	-
Pretax Income	8.03	10.33	6.21	4.15	2.03
Income Tax Expense	1.49	1.81	1.46	1.27	0.61
Earnings From Continuing Operations	6.54	8.51	4.76	2.88	1.41
Net Income to Company	6.54	8.51	4.76	2.88	-
Net Income	6.54	8.51	4.76	2.88	1.42
Net Income to Common	6.54	8.51	4.76	2.88	-
Net Income Growth	-23.11%	78.97%	65.25%	103.23%	230.07%
Free Cash Flow	-2.19	-4.74	-4.62	-4.14	-
Dividend Per Share	0.070	-	-	-	-
Gross Margin	68.61%	58.95%	53.94%	51.85%	76.61%
Operating Margin	20.11%	24.74%	19.75%	14.72%	11.30%
Profit Margin	16.23%	19.88%	14.72%	10.27%	-
Free Cash Flow Margin	-5.42%	-11.07%	-14.31%	-14.77%	-
EBITDA	9.43	11.6	6.85	4.42	2.32
EBITDA Margin	23.37%	27.09%	21.21%	15.79%	12.82%
D&A For EBITDA	1.32	1.01	0.47	0.3	-
EBIT	8.11	10.59	6.38	4.12	2.04
EBIT Margin	20.11%	24.74%	19.75%	14.72%	11.30%
Effective Tax Rate	18.50%	17.58%	23.46%	30.61%	-
Revenue as Reported	51.6	45.8	34.28	29.17	-

Updated Sep 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.